Regular dosage size is recommended at 20 drops, 1-2 times per day. According to the manufacturer, small to large dosage sizes are as follows: 250 mg = 1/4 dropper, or ~5 drops 300 mg = 3/10 dropper, or ~6 drops 500 mg = 1/2 dropper, or ~10 drops 600 mg = 3/5 dropper, or ~12 drops 800 mg = 4/5 dropper, or ~16 drops 1000 mg = 1 full dropper, or ~20 drops 1500 mg = 1 1/2 dropper, or ~30 drops
CBD may be best known for its relaxing, calming effects. CBD reduces autonomic arousal, having the inverse effect of THC on the body. CBD’s anti-anxiety effect is why many in the cannabis community talk about how CBD relieves paranoia, although that is not scientifically proven yet. CBD is also known for its anti-nausea and pain relieving effects. It really depends on why your body’s specific needs and the quantity in which you take CBD.
The most commonly used form of CBD is CBD oil. Combining CBD extract with a carrier oil like coconut oil, it can be ingested or vaped, bringing a lot of variety. But because marijuana legalization is in such a murky situation with both federal and state laws to grapple with, CBD oil's legality can be hard to parse depending on where you are. Let's start with legality at the federal level.
Even though CBD federal law now allows for cannabidiol to be used nationwide, it is critical that when purchasing CBD products that you buy products from reputable sources such as American Hemp Oil. Why? Because all our CBD products are made with extracts obtained from industrial hemp ensuring American Hemp Oil products comply with all legal regulations.
In 1970, the U.S. government passed the Controlled Substances Act, a statute that regulates all cannabis, including industrial hemp. However, the definition of marijuana was lifted from the existing 1937 statute and adopted without any change. This definition excluded certain parts of hemp — sterilized hemp seed, hemp fiber, and hemp seed oil — from regulation.
Generalized pain, for instance, has dozens upon dozens of high profile research and clinical studies that have been carried out in universities and laboratories around the globe. One of the most well-publicized of these studies took place back in 2008, in which results determined that “cannabinoid analgesics (pain relievers) have generally been well tolerated in clinical trials … with acceptable adverse event profiles (meaning acceptable effectiveness for practical use).